Navigation Links
Biopure Completes U.K. Regulatory Agency Inspection
Date:3/19/2008

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has completed its inspection of the company's Pennsylvania manufacturing facility. The inspection report contained no "Critical" and no "Major" deficiencies in compliance with good manufacturing practices. The MHRA report identified shortcomings characterized as "Other," with a request for a response detailing the company's corrective actions within 35 working days.

According to John Tomera, Director of Regulatory Affairs at Biopure, "We are pleased with the MHRA's inspection result, which attests to our efforts toward consistently maintaining quality standards. We anticipate being able readily to address all of the issues that were cited by the MHRA."

As previously announced, Biopure has pending with the MHRA a marketing authorization application to market Hemopure in the United Kingdom for acute anemia during elective orthopedic surgery where red blood cell transfusion is not available. The inspection is a routine part of the application procedure.

No inspection of the company's manufacturing facility in Massachusetts is scheduled at this time or expected to occur before the MHRA next communicates about the pending application.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Announces 2008 First Quarter Financial Results
2. Biopure Launches Updated Website
3. Biopure Announces Pricing of Equity Offering
4. Biopure Gives Update on Malaysia Joint Venture Discussions
5. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
8. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
9. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
10. Plurality Completes R&D of its HAL-256 Multicore Processor
11. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Frost & Sullivan is pleased to ... Corporation, will receive special recognition at the 22nd Annual Medical ... 19 to 21, 2017 at the Loews Coronado Bay Resort in ... register and download the event agenda for Medical Technologies 2017: A ... ...
(Date:1/24/2017)... WAYNE, Pa. , Jan. 24, 2017   ... services provider, today announced the addition of Jennifer ... new Senior Vice President and General Manager for the ... be responsible for Bracket,s work in Rater Training, Quality ... joins Bracket with a strong skillset and demonstrated record ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... underwriters have agreed to increase the size of the offering ... the Company, together with warrants to purchase 1,842,106 shares of ... US$5.50 per share of common stock (the "Exercise Price"), at ... associated warrant (the "Public Price"). The warrants have a term ...
(Date:1/24/2017)... CA (PRWEB) , ... January 24, 2017 , ... ... development of label-free graphene biosensor assays for fragment-based screening, will showcase ... the 2017 Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/16/2016)... Dec. 16, 2016 The global wearable medical device market, ... by 2021 from USD 5.31 billion in 2016, at a CAGR ... ... by technological advancements in medical devices, launch of a growing number ... wireless connectivity among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):